Movfor Molnupiravir 200 mg
Price range: $80.00 through $272.00
| Quantity Value | Price | Quantity | Add To Cart |
|---|---|---|---|
| 120 Capsules | $210.00 |
|
|
| 160 Capsules | $272.00 |
|
|
| 40 Capsules | $80.00 |
|
|
| 80 Capsules | $150.00 |
|
SKU : N/A
Category : Viral Care
Movfor Molnupiravir 200 mg is an oral antiviral medicine used to treat mild to moderate COVID-19 in adults at high risk of severe illness by reducing viral replication. It’s most effective when started early in the course of infection under medical supervision.
Movfor Molnupiravir 200 mg
Movfor Molnupiravir 200 mg is a prescription oral antiviral medication formulated to help treat mild to moderate coronavirus disease 2019 (COVID-19) in adults who are at increased risk of progressing to severe illness, hospitalization, or death. Its active ingredient, molnupiravir, belongs to a newer class of antivirals known as nucleoside analogues. These drugs work by disrupting a virus’s ability to replicate its genetic material, thereby reducing viral load and helping the immune system clear the infection more effectively.
Movfor Molnupiravir 200 mg is designed for outpatient use and is typically prescribed when other treatment options are limited or when early intervention is especially important — for example, in older adults and individuals with chronic health conditions like diabetes, heart disease, or compromised immune systems.
Mechanism of Action
Molnupiravir is a prodrug, meaning it is converted in the body into its active metabolite after absorption. The active form — N-hydroxycytidine (NHC) — resembles one of the building blocks of viral RNA. When the SARS-CoV-2 virus attempts to reproduce using its RNA-dependent RNA polymerase enzyme, NHC is mistakenly incorporated into the growing viral RNA strand. This incorporation introduces a high rate of mutations into the viral genome, leading to a phenomenon known as error catastrophe. As a result, the virus produces defective copies of itself that cannot continue to replicate effectively. This mechanism significantly reduces the amount of viable virus in the body and helps to blunt disease progression. (World Health Organization – Therapeutics)
Indications and Patient Use
Movfor Molnupiravir 200 mg is indicated for:
-
Treatment of mild to moderate COVID-19 in adults with a confirmed positive viral test
-
Patients at high risk of progression to severe disease, including the elderly and those with chronic health conditions
-
Use specifically for non-hospitalized patients who are not severely ill at the time of diagnosis
It is important to note that Movfor Molnupiravir is not approved for COVID-19 prevention (prophylaxis) and is not recommended for hospitalized patients with more severe disease requiring oxygen or inpatient care.
Dosage and Administration
The typical treatment regimen for Movfor Molnupiravir 200 mg involves:
-
800 mg per dose (equivalent to four 200 mg capsules)
-
Taken twice daily (every 12 hours)
-
Over a 5-day course
-
Treatment should begin as soon as possible and within 5 days of symptom onset
The capsules should be swallowed whole with water and may be taken with or without food. It is crucial to complete the entire prescribed course even if symptoms improve before the 5 days are up. Skipping doses or shortening the course can reduce effectiveness.
Benefits of Movfor Molnupiravir Treatment
When used appropriately and early in the infection, Movfor Molnupiravir 200 mg may:
-
Reduce the risk of progression to severe COVID-19
-
Lower the chance of hospitalization or death in high-risk adults
-
Decrease viral load more rapidly
-
Provide a convenient, outpatient therapy compared with intravenous treatments
Because it can be taken at home, the medicine offers a practical antiviral option for eligible patients under medical supervision.
Side Effects and Safety Considerations
Commonly reported side effects include:
-
Nausea
-
Diarrhea
-
Headache
-
Dizziness
These side effects are generally mild and transient. As with all medications, patients should discuss persistent or severe symptoms with their healthcare provider.
Because molnupiravir works by creating errors in viral RNA, it is not recommended during pregnancy due to potential risks. Women of childbearing potential should use effective contraception during treatment and for a specified period after the last dose. Similarly, male patients with partners of reproductive potential should consider contraceptive measures during treatment and for a short period afterward.
Precautions and Contraindications
Before starting Movfor Molnupiravir, patients should inform their doctor if they:
-
Are pregnant or breastfeeding
-
Are taking other medications that could interact with molnupiravir
-
Have underlying liver or kidney issues
-
Have a known allergy to molnupiravir or any capsule ingredient
The medication is currently not authorized for use in individuals under 18 years of age due to insufficient safety data in pediatric populations.
Storage and Handling
Movfor Molnupiravir 200 mg Capsules should be stored in a cool, dry place away from direct sunlight and moisture. Keep the medication out of the reach of children and pets.
External Link for More Information
For detailed, medically reviewed information about molnupiravir and its use in COVID-19 treatment, visit:
https://medlineplus.gov/druginfo/meds/a621008.html
| Pack Size |
120 Capsules ,160 Capsules ,40 Capsules ,80 Capsules |
|---|
Related products
Artecan 120 mg Injection
Artecan 120 mg Injection is a potent antimalarial medicine containing artesunate used to treat severe malaria caused by Plasmodium falciparum. It works rapidly to reduce parasite load and improve clinical outcomes when administered by a healthcare professional. (WHO – Malaria Treatment Guidelines)
